{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:00:43Z","timestamp":1784768443712,"version":"3.55.0"},"reference-count":12,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:sec id=\"ab-dbr240015-4\"><jats:title>Importance<\/jats:title><jats:p>Atopic dermatitis (AD) is the most prevalent chronic skin condition characterized by inflammation and itching. Currently, there is no reliable method for identifying which newborns might have an increased risk of developing AD.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr240015-5\"><jats:title>Objective<\/jats:title><jats:p>To evaluate the predictive value of serological biomarkers, such as CCL17\/thymus- and activation-regulated chemokine, CCL18, CCL22, CCL27, IL-31, and thymus stromal lymphopoietin, with transepidermal water loss (TEWL) and hydration rate and the development of AD in infants.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr240015-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This observational prospective study included 40 consecutive full-term newborns from a single university hospital in Pisa, Italy. The cutaneous markers of infants were assessed at 1, 6, and 12 months of age, while the biomarkers from the 10-mL sample of cord blood taken at birth were measured after delivery. Data were collected from March to December 2018 and analyzed from January to April 2019.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr240015-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Level of serological biomarkers associated with TEWL and hydration rate, as well as the emergence of AD during the first 12 months of life.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr240015-8\"><jats:title>Results<\/jats:title><jats:p>All 40 included infants (27 male [68%]) completed the study. At 6 months, 16 infants presented symptoms and signs of AD (AD group) and 24 did not (non-AD group). Infants with AD signs had statistically significant anterior cubital fossa TEWL values at 1, 6, and 12 months of age compared to those without AD signs. No statistically significant correlations were observed between the TEWL measured at the anterior part of knee and hydration rate at the anterior cubital fossa at first month in the 2 groups. With regard to the blood biomarkers, at birth those in the AD group vs the non-AD group had statistically significant higher levels of CCL17\/thymus- and activation-regulated chemokine (median [IQR], 716 [509-951] pg\/mL vs 419 [24-566] pg\/mL; <jats:italic>P<\/jats:italic>\u2009=\u2009.003) and IL-31 (median [IQR], 212 [114-409] pg\/mL vs 97 [52-277] pg\/mL; <jats:italic>P<\/jats:italic>\u2009=\u2009.04); in contrast, no statistically significant serum level differences were registered for thymus stromal lymphopoietin (median [IQR], 105 [66-295] pg\/mL vs 88 [43-187] pg\/mL), CCL18 (median [IQR], 1236 [1115-1605] pg\/mL vs 1255 [1188-1677] pg\/mL), CCL22 (median [IQR], 1032 [936-1454] pg\/mL vs 1096 [932-1536] pg\/mL), and CCL27 (median [IQR], 172 [122-251] pg\/mL vs 120 [90-265] pg\/mL).<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr240015-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this observational study, the analysis of TEWL at the anterior cubital fossa area occurred prior to and correlated with the clinical signs of AD. Quantification of cytokines indicated that assessing cord blood serum levels of CCL17 and IL-31 could offer new perspectives in identifying newborns who might be susceptible to AD. Larger studies are needed to validate these findings.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.3178","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T15:19:50Z","timestamp":1726067990000},"page":"1112","source":"Crossref","is-referenced-by-count":7,"title":["Cord Blood Serum Levels of IL-31 and CCL17, Cutaneous Markers, and Development of Atopic Dermatitis"],"prefix":"10.1001","volume":"160","author":[{"given":"Angelo Massimiliano","family":"D\u2019Erme","sequence":"first","affiliation":[{"name":"Unit of Dermatology, Department of Medical and Oncology Area, University of Pisa, Pisa, Italy"},{"name":"Unit of Dermatology, Hospital of Livorno, Livorno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Fidanzi","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Medical and Oncology Area, University of Pisa, Pisa, Italy"},{"name":"Unit of Dermatology, Hospital of Carrara, Carrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bevilacqua","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Medical and Oncology Area, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[{"name":"Medicine Campus, Christine K\u00fchne\u2013Center for Allergy Research and Education, Davos, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Tuoni","sequence":"additional","affiliation":[{"name":"Division of Neonatology and NICU, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Paolicchi","sequence":"additional","affiliation":[{"name":"Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Franzini","sequence":"additional","affiliation":[{"name":"Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Morganti","sequence":"additional","affiliation":[{"name":"Statistical Support to Clinical Trials Department, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Papadia","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Medical and Oncology Area, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Janowska","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Medical and Oncology Area, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Dini","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Medical and Oncology Area, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Romanelli","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Medical and Oncology Area, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"dbr240015r1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3510","article-title":"Prevalence and incidence of atopic dermatitis: a systematic review.","volume":"100","author":"Bylund","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"4S","key":"dbr240015r2","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","article-title":"Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go?","volume":"139","author":"Bieber","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"dbr240015r3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jaip.2019.09.014","article-title":"Predicting skin barrier dysfunction and atopic dermatitis in early infancy.","volume":"8","author":"Rehbinder","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"dbr240015r4","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council.","volume":"147","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"dbr240015r5","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","article-title":"ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.","volume":"34","author":"Wollenberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"dbr240015r6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.alit.2015.09.004","article-title":"Transepidermal water loss measurement during infancy can predict the subsequent development of atopic dermatitis regardless of filaggrin mutations.","volume":"65","author":"Horimukai","year":"2016","journal-title":"Allergol Int"},{"issue":"4","key":"dbr240015r7","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jaci.2015.12.1312","article-title":"Skin barrier impairment at birth predicts food allergy at 2 years of age.","volume":"137","author":"Kelleher","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"dbr240015r8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.jaci.2023.01.019","article-title":"Biomarkers in atopic dermatitis.","volume":"151","author":"Bakker","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"dbr240015r9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/all.15518","article-title":"Skin biomarkers predict development of atopic dermatitis in infancy.","volume":"78","author":"Rinnov","year":"2023","journal-title":"Allergy"},{"issue":"1","key":"dbr240015r10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2500\/aap.2020.41.190016","article-title":"Correlation of serum interleukin-31 with pruritus and blood eosinophil markers in children with atopic dermatitis.","volume":"41","author":"Byeon","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"dbr240015r11","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/438963","article-title":"The role of cytokines, chemokines, and growth factors in the pathogenesis of pityriasis rosea.","volume":"2015","author":"Drago","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"4","key":"dbr240015r12","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/all.15491","article-title":"Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants\u2014the STOP-AD randomised controlled trial.","volume":"78","author":"N\u00ed Chaoimh","year":"2023","journal-title":"Allergy"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2823481\/jamadermatology_derme_2024_br_240015_1729089118.46028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T15:06:55Z","timestamp":1729091215000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2823481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.3178","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}